%0 Journal Article
%T Uso de vacuna Valergen DP en la rinitis al¨¦rgica
%A Sugra£¿es Montalv¨¢n
%A Adianez
%A Hern¨¢ndez Veiga
%A Marelys
%A Morales Men¨¦ndez
%A Mar¨ªa
%A Barreto Su¨¢rez
%A Eduardo
%A Sugra£¿es Montalv¨¢n
%A Arianna
%A Ram¨ªrez Torres
%A Andr¨¦s
%J Revista Archivo M£¿£¿dico de Camag£¿£¿ey
%D 2011
%I Centro Provincial de Informaci¨®n de Ciencias M¨¦dicas de Camag¨¹ey
%X background: allergic rhinitis produced a significant deterioration in the quality of life. sublingual immunotherapy represents a natural way to induce tolerance in the allergic disorder. objective: to assess the efficacy and safety of allergenic extract valergen-dp from mite dermatophagoides pteronyssinus as sublingual therapeutic vaccine in patients with allergic rhinitis. method: a clinical trial, phase ii, double-blind, parallel, randomized, controlled with a placebo group was conducted. vaccines were provided via sublingual in an increasing dose schedule. the treatment had a minimal duration of one year with frequent evaluations. the 40 patients included, two groups of 20 were assigned, previous informed consent. results: it was observed an average decrease in the mean of symptoms, as well as drugs consumption in the active group in relation to the placebo with 156,3 (p=0,000) and 43.5 (p = 0, 000) respectively. values of the mean of skin reactivity declined in the active group not so in the placebo with 2.6 %. only four adverse events were reported, none fatal, representing a 0.2 %. conclusions: sublingual immunotherapy with dermatophagoide pteronyssinus is safe and effective for the treatment of patients with allergic rhinitis.
%K immunotherapy
%K active
%K dermatophagoides pteronyssinus
%K rhinitis
%K clinical trial
%K phase ii
%K administration
%K sublingual.
%U http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1025-02552011000400005&lng=en&nrm=iso&tlng=en